Understanding blood cancers in children to improve treatment outcomes
Official title: COG NCTN Integrated Translational Science Center for Hematopoietic Malignancies in Children
Funded at Public Health Institute · NIH-11249072 · Data updated 2026-11-12
This study is looking at blood cancers like leukemia and lymphoma in kids to find better treatments that are less harsh, so young patients can have a better chance of recovery and a happier life after treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Public Health Institute NIH-funded |
| Lab location | 1 site (Oakland, United States) |
| Project start | March 1, 2022 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $480,000 |
| NIH project number | 3UG1CA233249-06S1 |
| Project ID | NIH-11249072 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include children diagnosed with hematopoietic malignancies such as leukemia or lymphoma.
✕Less likely to help
Patients with non-hematopoietic cancers or those who are not children may not receive benefits from this research.
What this research studies
This research focuses on hematopoietic malignancies, such as leukemias and lymphomas, which are significant causes of cancer-related deaths in children. The Children's Oncology Group (COG) aims to enhance treatment outcomes by identifying the biological basis of these cancers, which could lead to more targeted therapies. By studying the unique characteristics of these malignancies, the research seeks to minimize the use of harsh cytotoxic therapies and improve the quality of life for survivors. The project involves collaboration with the National Cancer Institute to conduct discovery phase studies that will help pinpoint specific targets for therapy.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less harmful treatments for children with blood cancers.
How similar studies have gone: Previous research has shown success in identifying targeted therapies for certain blood cancers, indicating a promising direction for this study.
Where this research is happening
-
Public Health Institute
Oakland, United States Active
Researchers
- Principal investigator: Meshinchi, Soheil — Public Health Institute
- Study coordinator: Meshinchi, Soheil
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.